search
Back to results

Nasopharyngeal Carriage of S. Pneumoniae

Primary Purpose

Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
nasopharyngeal sample
Stools collection or anorectal swab samples
Sponsored by
Association Clinique Thérapeutique Infantile du val de Marne
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Nasopharyngeal Carriage focused on measuring Pneumococcal conjugate vaccine, Streptococcus pneumoniae, Carriage

Eligibility Criteria

6 Months - 15 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • both sexes
  • suffering from suppurative AOM
  • age: 6 months to 24 months for AOM
  • age: 6 months to 15 years for healthy children
  • informed consent from parents or guardians

Exclusion Criteria:

  • Children with antibiotic treatment within 7 days before enrolment,
  • severe underlying disease,
  • inclusion in the study during the previous 12 months

Sites / Locations

  • ACTIVRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

prospective cohort

ESBL cohort

Arm Description

Nasopharyngeal sample for each enrolled children

Stool or anorectal swab samples for a subgroup of children

Outcomes

Primary Outcome Measures

S. Pneumoniae colonisation to detect emerging serotypes
The percentage of children colonised by non vaccine serotypes -

Secondary Outcome Measures

Detect the emergence of resistance S. pneumoniae
Percentage of penicillin resistant S. pneumoniae
Evaluation of the rhinopharyngeal carriage of other bacteria
Haemophilus influenzae, Moraxella Catarrhalis, and Staphylococcus aureus in AOM group and healthy children.
Detect the emergence of new serotypes
> 10 Percent of isolated Sp, 5 percent of carrier children
For the ancillary study, the resistance of E. coli (ESBL) will be evaluated.
Assessment of E. coli (ESBL) resistance.

Full Information

First Posted
June 19, 2020
Last Updated
December 22, 2022
Sponsor
Association Clinique Thérapeutique Infantile du val de Marne
Collaborators
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT04460313
Brief Title
Nasopharyngeal Carriage of S. Pneumoniae
Official Title
Observatory of Nasopharyngeal Carriage of Streptococcus Pneumoniae (Sp) in Infants With Acute Otitis and in Healthy Child - Ancillary Study for Detection of E Coli ESBL Carriers
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 11, 2001 (Actual)
Primary Completion Date
December 1, 2024 (Anticipated)
Study Completion Date
December 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Association Clinique Thérapeutique Infantile du val de Marne
Collaborators
Pfizer

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This nasopharyngeal (NP) carriage surveillance study was requested by the European Agency for the Evaluation of Medicinal Products as a post-licensing commitment to determine whether the use of the pneumococcal conjugate vaccines (PCVs) including 7 then 13 valents (introduced in 2001 and 2010, respectively) caused a shift in the distribution of Streptococcus pneumoniae serotypes in children with acute otitis media and modified the resistance of this bacterial species to antibiotics.
Detailed Description
Since September 2001, 121 pediatricians who are part of a research and teaching network (ACTIV) throughout France participated at this prospective study. From October to June of each subsequent year, children of both sexes suffering from suppurative acute otitis media (AOM) with fever and/or otalgia (in order to increase the probability of pneumococcal AOM), aged 6 to 24 months, were enrolled. And a second group of healthy children aged 6 months to 15 years were also enrolled for the main study. For ancillary study a subgroup of children were enrolled for assessment of E. coli (ESBL) resistance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain
Keywords
Pneumococcal conjugate vaccine, Streptococcus pneumoniae, Carriage

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
multicenter nationwide prospective cohort
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
23560 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
prospective cohort
Arm Type
Other
Arm Description
Nasopharyngeal sample for each enrolled children
Arm Title
ESBL cohort
Arm Type
Other
Arm Description
Stool or anorectal swab samples for a subgroup of children
Intervention Type
Other
Intervention Name(s)
nasopharyngeal sample
Intervention Description
Nasopharyngeal swabs from children with acute otitis media aged 6 to 24 months. The swabs were analyzed by the French National Reference Centre for Pneumococci.
Intervention Type
Other
Intervention Name(s)
Stools collection or anorectal swab samples
Intervention Description
For a subgroup of children stools samples or anorectal swab samples were collected for assessment of E. coli (ESBL) resistance
Primary Outcome Measure Information:
Title
S. Pneumoniae colonisation to detect emerging serotypes
Description
The percentage of children colonised by non vaccine serotypes -
Time Frame
at inclusion
Secondary Outcome Measure Information:
Title
Detect the emergence of resistance S. pneumoniae
Description
Percentage of penicillin resistant S. pneumoniae
Time Frame
at inclusion
Title
Evaluation of the rhinopharyngeal carriage of other bacteria
Description
Haemophilus influenzae, Moraxella Catarrhalis, and Staphylococcus aureus in AOM group and healthy children.
Time Frame
at inclusion
Title
Detect the emergence of new serotypes
Description
> 10 Percent of isolated Sp, 5 percent of carrier children
Time Frame
at inclusion
Title
For the ancillary study, the resistance of E. coli (ESBL) will be evaluated.
Description
Assessment of E. coli (ESBL) resistance.
Time Frame
at inclusion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: both sexes suffering from suppurative AOM age: 6 months to 24 months for AOM age: 6 months to 15 years for healthy children informed consent from parents or guardians Exclusion Criteria: Children with antibiotic treatment within 7 days before enrolment, severe underlying disease, inclusion in the study during the previous 12 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Corinne Levy, MD
Phone
0033148850404
Email
corinne.levy@activ-france.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Stéphane Béchet, MsC
Phone
0033148850404
Email
stephane.bechet@activ-france.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Cohen, MD
Organizational Affiliation
Association Clinique Thérapeutique Infantile du val de Marne
Official's Role
Principal Investigator
Facility Information:
Facility Name
ACTIV
City
Créteil
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Corinne Levy, MD
Phone
0033148850404
Email
corinne.levy@activ-france.fr
First Name & Middle Initial & Last Name & Degree
Stéphane Béchet, MSc
Phone
0033148850404
Email
stephane.bechet@activ-france.fr

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31280295
Citation
Ouldali N, Cohen R, Levy C, Gelbert-Baudino N, Seror E, Corrard F, Vie Le Sage F, Michot AS, Romain O, Bechet S, Bonacorsi S, Angoulvant F, Varon E. Pneumococcal susceptibility to antibiotics in carriage: a 17 year time series analysis of the adaptive evolution of non-vaccine emerging serotypes to a new selective pressure environment. J Antimicrob Chemother. 2019 Oct 1;74(10):3077-3086. doi: 10.1093/jac/dkz281.
Results Reference
result
PubMed Identifier
29227464
Citation
Rybak A, Levy C, Bonacorsi S, Bechet S, Vie le Sage F, Elbez A, Varon E, Cohen R. Antibiotic Resistance of Potential Otopathogens Isolated From Nasopharyngeal Flora of Children With Acute Otitis Media Before, During and After Pneumococcal Conjugate Vaccines Implementation. Pediatr Infect Dis J. 2018 Mar;37(3):e72-e78. doi: 10.1097/INF.0000000000001862.
Results Reference
result
PubMed Identifier
28418829
Citation
Birgy A, Bidet P, Levy C, Sobral E, Cohen R, Bonacorsi S. CTX-M-27-Producing Escherichia coli of Sequence Type 131 and Clade C1-M27, France. Emerg Infect Dis. 2017 May;23(5):885. doi: 10.3201/eid2305.161865. No abstract available.
Results Reference
result
PubMed Identifier
26271823
Citation
Cohen R, Varon E, Doit C, Schlemmer C, Romain O, Thollot F, Bechet S, Bonacorsi S, Levy C. A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation. Vaccine. 2015 Sep 22;33(39):5118-26. doi: 10.1016/j.vaccine.2015.08.010. Epub 2015 Aug 11.
Results Reference
result
PubMed Identifier
21501471
Citation
Cohen R, Levy C, Bonnet E, Thollot F, Boucherat M, Fritzell B, Derkx V, Bingen E, Varon E. Risk factors for serotype 19A carriage after introduction of 7-valent pneumococcal vaccination. BMC Infect Dis. 2011 Apr 18;11:95. doi: 10.1186/1471-2334-11-95.
Results Reference
result
PubMed Identifier
22397629
Citation
Cohen R, Bingen E, Levy C, Thollot F, Boucherat M, Derkx V, Varon E. Nasopharyngeal flora in children with acute otitis media before and after implementation of 7 valent pneumococcal conjugate vaccine in France. BMC Infect Dis. 2012 Mar 7;12:52. doi: 10.1186/1471-2334-12-52.
Results Reference
result
PubMed Identifier
29637893
Citation
Levy C, Vie le Sage F, Varon E, Chalumeau M, Grimprel E, Cohen R. Pediatric Ambulatory and Hospital Networks for Surveillance and Clinical Epidemiology of Community-Acquired Infections. J Pediatr. 2018 Mar;194:269-270.e2. doi: 10.1016/j.jpeds.2017.11.050. Epub 2018 Feb 22. No abstract available.
Results Reference
result
PubMed Identifier
30634919
Citation
Vermee Q, Cohen R, Hays C, Varon E, Bonacorsi S, Bechet S, Thollot F, Corrard F, Poyart C, Levy C, Raymond J. Biofilm production by Haemophilus influenzae and Streptococcus pneumoniae isolated from the nasopharynx of children with acute otitis media. BMC Infect Dis. 2019 Jan 11;19(1):44. doi: 10.1186/s12879-018-3657-9.
Results Reference
result
PubMed Identifier
31617912
Citation
Birgy A, Madhi F, Jung C, Levy C, Cointe A, Bidet P, Hobson CA, Bechet S, Sobral E, Vuthien H, Ferroni A, Aberrane S, Cuzon G, Beraud L, Gajdos V, Launay E, Pinquier D, Haas H, Desmarest M, Dommergues MA, Cohen R, Bonacorsi S; Group of the National Observatory of Urinary tract Infection due to ESBL-producing Enterobacteriaceae in children. Diversity and trends in population structure of ESBL-producing Enterobacteriaceae in febrile urinary tract infections in children in France from 2014 to 2017. J Antimicrob Chemother. 2020 Jan 1;75(1):96-105. doi: 10.1093/jac/dkz423.
Results Reference
result
PubMed Identifier
25037572
Citation
Mizrahi A, Cohen R, Varon E, Bonacorsi S, Bechet S, Poyart C, Levy C, Raymond J. Non typable-Haemophilus influenzae biofilm formation and acute otitis media. BMC Infect Dis. 2014 Jul 19;14:400. doi: 10.1186/1471-2334-14-400.
Results Reference
result
PubMed Identifier
27330068
Citation
Birgy A, Levy C, Bidet P, Thollot F, Derkx V, Bechet S, Mariani-Kurkdjian P, Cohen R, Bonacorsi S. ESBL-producing Escherichia coli ST131 versus non-ST131: evolution and risk factors of carriage among French children in the community between 2010 and 2015. J Antimicrob Chemother. 2016 Oct;71(10):2949-56. doi: 10.1093/jac/dkw219. Epub 2016 Jun 20.
Results Reference
result
PubMed Identifier
23963858
Citation
Hau I, Levy C, Caeymaex L, Cohen R. Impact of pneumococcal conjugate vaccines on microbial epidemiology and clinical outcomes of acute otitis media. Paediatr Drugs. 2014 Feb;16(1):1-12. doi: 10.1007/s40272-013-0044-2.
Results Reference
result
PubMed Identifier
23171127
Citation
Birgy A, Cohen R, Levy C, Bidet P, Courroux C, Benani M, Thollot F, Bingen E. Community faecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in French children. BMC Infect Dis. 2012 Nov 21;12:315. doi: 10.1186/1471-2334-12-315.
Results Reference
result
PubMed Identifier
24263220
Citation
Caeymaex L, Varon E, Levy C, Bechet S, Derkx V, Desvignes V, Doit C, Cohen R. Characteristics and outcomes of acute otitis media in children carrying streptococcus pneumoniae or haemophilus influenzae in their nasopharynx as a single otopathogen after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2014 May;33(5):533-6. doi: 10.1097/INF.0000000000000213.
Results Reference
result
PubMed Identifier
22330166
Citation
Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012 Mar;31(3):297-301. doi: 10.1097/INF.0b013e318247ef84.
Results Reference
result
PubMed Identifier
22925540
Citation
Cohen R, Levy C, Bingen E, Bechet S, Derkx V, Werner A, Koskas M, Varon E. [Nasopharyngeal carriage of children 6 to 60 months during the implementation of the 13-valent pneumococcal conjugate vaccine]. Arch Pediatr. 2012 Oct;19(10):1132-9. doi: 10.1016/j.arcped.2012.07.013. Epub 2012 Aug 24. French.
Results Reference
result
PubMed Identifier
18190319
Citation
Cohen R, Levy C, Thollot F, de La Rocque F, Koskas M, Bonnet E, Fritzell B, Varon E. Pneumococcal conjugate vaccine does not influence Staphylococcus aureus carriage in young children with acute otitis media. Clin Infect Dis. 2007 Dec 15;45(12):1583-7. doi: 10.1086/523734. Erratum In: Clin Infect Dis. 2008 Feb 1;46(3):489.
Results Reference
result
PubMed Identifier
17072121
Citation
Cohen R, Levy C, de La Rocque F, Gelbert N, Wollner A, Fritzell B, Bonnet E, Tetelboum R, Varon E. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J. 2006 Nov;25(11):1001-7. doi: 10.1097/01.inf.0000243163.85163.a8.
Results Reference
result
Links:
URL
https://www.activ-france.com/fr/publications
Description
ACTIV publications

Learn more about this trial

Nasopharyngeal Carriage of S. Pneumoniae

We'll reach out to this number within 24 hrs